Check the evidence
Keep animal findings, people’s reports and comparisons between treatments in separate piles.
≈80people received BPC-157 across the human studies counted by FDA, as reviewed in September 2026.
US medicine reviews are carried out by the Food and Drug Administration (FDA). It found five human studies of this substance.
Two of the studies compared treatments. Their results were shared in short reports for research meetings. No full paper with the study details was published.
Evidence card · knee and bladder reports
Small reports on knee pain and a painful bladder condition described improvement, but neither had a comparison group to test whether BPC-157 caused it.
A comparison group lets researchers check what happens with a different treatment or a dummy treatment.
Read the FDA’s human-study summaryEvidence card · bowel-disease trial
In the bowel-disease study, the results did not clearly show that people given BPC-157 did better than people given a dummy treatment. FDA said these results were not enough to show it works for ulcerative colitis, a disease that causes swelling and irritation in the bowel.
That is an evidence limit; it does not prove that the substance cannot work.
Read the FDA’s assessment of that trialEvidence card · new trials
In China, a BPC-157 study for hamstring strains began in February 2026; the hamstrings are muscles on the back of the thigh. The planned US study after shoulder surgery had not started by September 2026. Neither had reported results.
ClinicalTrials.gov is the US government’s public list of studies. It shows their plans, progress and results when posted.
Ask the doctor to explain any results offered as support for a treatment claim.
Open the government trial search
In rat studies, BPC-157 helped injured tendons heal; tendons are the strong cords that join muscles to bones. Results in rats do not establish that it helps people.
For an injury claim, ask for a completed comparison study in people with that injury.